{
    "Clinical Trial ID": "NCT00033514",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Treatment Phase 1 Plus Phase 2",
        "  trastuzumab: Day 1 4mg/kg IV 2 mg/kg IV weekly.",
        "  erlotinib hydrochloride: 150 mg daily."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Women aged > 18 years",
        "  Histologically documents metastatic breast cancer",
        "  HER2 positive using Fluorescence In Situ Hybridization (FISH)",
        "  For phase I, patients who have previously received treatment for their metastatic disease are allowed to participate.",
        "  For the phase II portion of the study, patients must have measureable disease (> 2 cm; > 1 cm on spiral CT scan)",
        "  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2",
        "  A life expectancy of > 3 months",
        "  Use of effective means of contraception",
        "Exclusion Criteria:",
        "  For Phase II, prior cytotoxic chemotherapy and/or prior Herceptin for their metastatic disease. Prior treatment in the adjuvant setting is allowed."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  The Objective Response Rate as Defined as Stable Disease or the Rate of Complete and Partial Responses Determined on Two Consecutive Occasions Greater Than or Equal to 4 Weeks Apart.",
        "  Complete Response:",
        "  The disappearance of all signs of cancer in response to treatment. This does not always mean the cancer has been cured. Also called complete remission.",
        "  Partial Response:",
        "  A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment. Also called partial remission.",
        "  Time frame: 5 years",
        "Results 1: ",
        "  Arm/Group Title: Treatment Phase 1 Plus Phase 2",
        "  Arm/Group Description: trastuzumab: Day 1 4mg/kg IV 2 mg/kg IV weekly.",
        "  erlotinib hydrochloride: 150 mg daily.",
        "  Overall Number of Participants Analyzed: 12",
        "  Measure Type: Number",
        "  Unit of Measure: participants  Partial Response: 4",
        "Stable Disease: 1"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 16/27 (59.26%)",
        "  Dyspnea * 6/27 (22.22%)",
        "  hypertension with headache * 1/27 (3.70%)",
        "  pain/chest pressure/SOB *  [1]1/27 (3.70%)",
        "  LVEF less than the lower limit of normal * 2/27 (7.41%)",
        "  subendocardial myocardial infarction * 1/27 (3.70%)",
        "  dehydration/pain management * 1/27 (3.70%)",
        "  gastroenteritis *  [2]1/27 (3.70%)",
        "  progressive brain mets * 2/27 (7.41%)"
    ]
}